CG Oncology's Bladder Cancer Drug Shows 89.5% 6-Month EFS, High CR Rates in Phase 2 Trial
CGON has more than doubled off its 52-week low of $23.32.
Summary
CG Oncology reported highly positive first results from its CORE-008 Cohort CX Phase 2 trial, evaluating its intravesical combination therapy for high-risk non-muscle invasive bladder cancer (NMIBC) in BCG-exposed and BCG-unresponsive patients. The study demonstrated impressive complete response (CR) rates of 85.7% in the ITT population and 92.3% in the efficacy evaluable population for CIS-containing patients, alongside robust high-grade event-free survival (HG-EFS) of 89.5% at 6 months. Crucially, the therapy exhibited a favorable safety profile with no Grade 3 or greater treatment-related adverse events. This announcement follows the company's prior disclosure on May 11th about presenting at the AUA 2026 Annual Meeting, where these specific data will be detailed. These strong Phase 2 results significantly de-risk cretostimogene grenadenorepvec, a pivotal pipeline asset, and underscore its potential as an effective, bladder-sparing treatment option for a challenging patient population. The positive data could substantially enhance the drug's commercial prospects and drive significant investor interest. Traders should monitor for durability data expected later this year and any subsequent regulatory updates.
At the time of this announcement, CGON was trading at $69.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1B. The 52-week trading range was $23.32 to $75.50. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.